The drugs clearing Alzheimer’s brain plaques aren’t helping patients — and that’s a problem
The most advanced Alzheimer’s treatments ever developed can now demonstrably remove the protein clumps long blamed for the disease. Patients, however, are barely improving.
Anti-amyloid immunotherapies represent the culmination of decades of effort targeting beta-amyloid, a protein that accumulates in the brains of Alzheimer’s patients as sticky plaques. The dominant theory — the amyloid cascade hypothesis — held that these plaques drive the disease. Remove them, the thinking went, and you halt or reverse cognitive decline. The newest generation of these drugs does exactly what was asked of them: the plaques come out. The problem is that patients don’t get meaningfully better.
A recent review on Fight Aging! draws together the clinical trial data and arrives at a blunt conclusion. Even in early-stage patients, where the treatment logic is strongest, the clinical benefit is minimal to nonexistent. Memory does not recover. Cognitive decline is not substantially slowed. The target is hit. The disease continues.
When removing the evidence doesn’t solve the crime
This forces an uncomfortable question: is beta-amyloid the cause of Alzheimer’s, a symptom of something else, or possibly even a protective response the brain produces in reaction to a deeper problem? Sceptics of the amyloid hypothesis have long pointed out that some people carry heavy plaque loads without any dementia, while others develop severe Alzheimer’s with relatively modest amyloid burden. For years these were treated as exceptions. Now that drugs can clear the plaques without reversing the disease, that explanation is becoming harder to sustain.
The research community is divided. Some advocate pushing treatment even earlier — intervening before any symptoms appear, in the hope that plaques cause damage only after years of accumulation. Others argue the hypothesis is fundamentally flawed and that the field has over-invested in a single biological target for too long. Tau protein tangles, neuroinflammation, mitochondrial dysfunction, and vascular factors are all under investigation as alternative or contributing mechanisms.
What a dominant theory costs
The Alzheimer’s story is also a story about how science can get stuck. When one hypothesis dominates a field for thirty years, it shapes not just research funding but publication culture, career incentives, and the willingness of journals to accept inconvenient findings. Changing course is hard, even when the data suggest it’s necessary.
The most defensible reading of the current evidence is that amyloid-beta plaques are probably not the sole or primary cause of Alzheimer’s. The disease is likely a convergence of multiple processes, and removing one molecular player does not resolve the rest. What happens next in the field — and how quickly it is willing to accept that reality — will determine whether the next decade produces treatments that actually work for the millions of people still waiting.